Diagnostic techniques and prognostic indicators

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Chavan SS et al. Blood Cancer J. 2017 Feb 24;7(2):e535. doi: 10.1038/bcj.2017.12. CD117 (KIT) Is A Useful Marker in The Diagnosis of Plasmablastic Plasma Cell Myeloma. Marks E et al. Histopathology. 2017 Feb 22. doi: 10.1111/his.13196. [Epub ahead of print]. In vivo confocal microscopy of multiple myeloma associated…

Details

Related conditions

Periorbital papules as a presenting sign in multiple myeloma with AL amyloidosis. Vilcassim FS et al. BMJ Case Rep. 2017 Feb 20;2017. pii: bcr2016219010. doi: 10.1136/bcr-2016-219010. Amyloidosis: A cancer-derived paraproteinemia and kidney involvement. Małyszko J et al. Adv Med Sci. 2017 Jan 30;62(1):31-38. doi: 10.1016/j.advms.2016.06.004. [Epub ahead of print]. Pure Red Cell Aplasia Associated with Monoclonal Gammopathy of Undetermined Significance and Literature Review.…

Details

Emerging treatments

Conditioning regimens for autologous haematopoietic stem cell transplantation – can natural killer cell therapy help? Snowden JA et al. Br J Haematol. 2017 Feb 17. doi: 10.1111/bjh.14565. [Epub ahead of print]. Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. Vogl DT et al. Leuk Lymphoma. 2017 Jan 31:1-11. doi: 10.1080/10428194.2016.1263842. [Epub ahead of print].…

Details

Biology and genetics

Mutational landscape reflects the biological continuum of plasma cell dyscrasias. Rossi A et al. Blood Cancer J. 2017 Feb 24;7(2):e537. doi: 10.1038/bcj.2017.19. Ecto-5′ -Nucleotidase CD73 (NT5E), vitamin D receptor and FGF23 gene polymorphisms may play a role in the development of calcific uremic arteriolopathy in dialysis patients – Data from the German Calciphylaxis Registry. Rothe H et al. PLoS One. 2017…

Details

General

Multiple myeloma: routes to diagnosis, clinical characteristics and survival – findings from a UK population-based study. Howell D et al. Br J Haematol. 2017 Feb 1. doi: 10.1111/bjh.14513. [Epub ahead of print]. High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting. Lisenko K et al. BMC Cancer. 2017 Feb 22;17(1):151. doi: 10.1186/s12885-017-3137-4. Association between response rates…

Details

Supportive treatments

Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database. Palmaro A et al. Pharmacoepidemiol Drug Saf. 2017 Feb 15. doi: 10.1002/pds.4180. [Epub ahead of print]. Associations of high-dose melphalan pharmacokinetics and outcomes in the setting of a randomized cryotherapy trial. Cho YK et al. Clin Pharmacol Ther. 2017 Feb 4. doi: 10.1002/cpt.644. [Epub…

Details

Complications of myeloma and its treatments

Renal failure in multiple myeloma: something new on the horizon. Offidani M et al. Br J Haematol. 2017 Feb 17. doi: 10.1111/bjh.14548. [Epub ahead of print]. Delphi-based study and analysis of key risk factors for invasive fungal infection in haematological patients. Vázquez L et al. Rev Esp Quimioter. 2017 Feb 14. pii: vazquez14feb2017. [Epub ahead of print]. Myelosuppression-sparing treatment of central nervous…

Details

Current treatments

Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy. Berdeja JG et al. Br J Haematol. 2017 Feb 7. doi: 10.1111/bjh.14536. [Epub ahead of print]. Impact of induction treatment before autologous stem cell transplantation on long term outcome in patients with newly diagnosed multiple…

Details